Chen T B, Lotti V J, Chang R S
New Lead Pharmacology, Merck Research Laboratories, West Point, Pennsylvania 19486.
Mol Pharmacol. 1992 Dec;42(6):1077-82.
[3H]L-158,809, a new potent and AT1-selective nonpeptide angiotensin II receptor antagonist, bound saturably and reversibly to rat adrenal membranes. Scatchard and Hill plot analyses indicated a single class of high affinity (Kd = 0.66 nM) binding sites. The relative potencies of various angiotensin II-related peptide and nonpeptide antagonists in displacing [3H]L-158,809 binding correlated with their potencies in displacing the binding of 125I-Sar1,Ile8-angiotensin II to adrenal AT1 receptors. [3H]L-158,809 binding to adrenal membranes was not affected by addition of guanosine-5'-(beta,gamma-imido)triphosphate or various pharmacological agents known to interact with other common peptide and nonpeptide receptor systems. The potencies of angiotensin II receptor agonists, but not antagonists, in inhibiting specific [3H]L-158,809 binding were decreased in the presence of guanosine-5'-(beta,gamma-imido)triphosphate. Specific [3H]L-158,809 binding was also observed in rat liver and kidney. Collectively, the data indicate that [3H]L-158,809 represents a new, potent, nonpeptide, antagonist radioligand suitable for the study of angiotensin II AT1 receptors.
[3H]L-158,809是一种新型强效且对AT1具有选择性的非肽类血管紧张素II受体拮抗剂,它能与大鼠肾上腺膜饱和且可逆地结合。Scatchard和Hill作图分析表明存在一类单一的高亲和力(Kd = 0.66 nM)结合位点。各种血管紧张素II相关肽和非肽拮抗剂在取代[3H]L-158,809结合方面的相对效力与其在取代125I-Sar1,Ile8-血管紧张素II与肾上腺AT1受体结合方面的效力相关。向肾上腺膜中添加鸟苷-5'-(β,γ-亚氨基)三磷酸或已知与其他常见肽和非肽受体系统相互作用的各种药理剂,不会影响[3H]L-158,809与肾上腺膜的结合。在存在鸟苷-5'-(β,γ-亚氨基)三磷酸的情况下,血管紧张素II受体激动剂(而非拮抗剂)抑制特异性[3H]L-158,809结合的效力会降低。在大鼠肝脏和肾脏中也观察到了特异性[3H]L-158,809结合。总体而言,数据表明[3H]L-158,809是一种新型、强效、非肽类拮抗剂放射性配体,适用于研究血管紧张素II AT1受体。